In vitro susceptibility of chromoblastomycosis and phaeohyphomycosis agents to antifungal drugs

References

• Rippon JW (ed). Chromoblastomycosis. In: Medical Mycology. The Pathogenic Fungi and the Pathogenic Actinomycetes, 3rd edn. Philadelphia: WB Saunders, 1988; 276–296.
   Google Scholar
• McGinnis MR. Chromoblastomycosis and phaeohyphomyco-sis: new concepts, diagnosis, and mycology. J Am Acad Derma-tol 1983; 8: 1–16.
   PubMed Web of Science ®Google Scholar
• de Hoog GS. Significance of fungal evolution for the under-standing of their pathogenicity, illustrated with agents of phaeohyphomycosis. Mycoses 1997; 40: 5–8.
   PubMed Web of Science ®Google Scholar
• Dixon DM, Szaniszlo PJ, Polak A. Dihydroxynaphthalene (DNH) melanin and its relationship with virulence in the early stages of phaeohyphomycosis. In: Cole GT, Hoch HC, eds. The Fungal Spore, and Disease Initiation in Plants and Animals. New York: Plenum Press, 1991; 297–318.
   Google Scholar
• Tintelnot K. Therapy of infections caused by dematiaceous fungi. Mycoses 1997; 40: 91–96.
   PubMed Web of Science ®Google Scholar
• Pavlidakey G, Snow S, Mohs F. Chromoblastomycosis treated by Mohs micrographic surgery. J Dermatol Surg Oncol 1986; 12: 1073–1075.
   PubMed Web of Science ®Google Scholar
• Chuan MT, Wu MC. Subcutaneous phaeohyphomycosis caused by Exophiala jeanselmei: successful treatment with itra-conazole. Int J Dermatol 1995; 34: 563–566.
   PubMed Web of Science ®Google Scholar
• Lopes CF, Resende MA, Alvarenga RJ, Moreira YK. Asso-ciacao de 5-fluorocitosina e anfotericina B no tratamento da cromomicose. Med Cut Ibero Latino Americana 1979; 13: 1–8.
   Google Scholar
• Silber JG, Gombert ME, Green KM, Shalita AR. Treatment of chromoblastomycosis with ketoconazole and 5-fluorocytosine. J Am Acad Dermatol 1983; 8: 236–238.
   PubMed Web of Science ®Google Scholar
• Restrepo A. Treatment of topical mycoses. J Am Acad Derma-tol 1994; 31: 91–102.
   PubMed Web of Science ®Google Scholar
• Randhawa HS, Budimulja U, Bazaz-Malik G, et al. Recent developments in the diagnosis and treatment of subcutaneous mycoses. J Med Vet Mycol 1994; 32: 299–307.
   Google Scholar
• Bonifaz A, Martinez-Soto E, Carrasco-Gerard E, Peniche J. Treatment of chromoblastomycosis with itraconazole, cryosurgery, and a combination of both. Int J Dermatol 1997; 36 (7): 542–547.
   PubMed Web of Science ®Google Scholar
• Esterre P, Inzan CK, Ramarcel ER, et al. Treatment of chro-momycosis with terbinafine: preliminary results of an open pilot study. Brit J Dermatol 1996; 134: 33–36.
   PubMed Web of Science ®Google Scholar
• Stevens DA. Antifungal drug susceptibility testing. Myco-pathology 1984; 87: 135–140.
   Google Scholar
• Espinel-Ingroff A, Shadomy S. In vitro and in vivo evaluation of antifungal agents. Eur J Clin Microbiol Infect Dis 1988; 8: 352–361.
   Google Scholar
• Cardona-Castro N, Agudelo-Flórez P, Restrepo-Molina R. Chromoblastomycosis murine model and in vitro test to evalu-ate the sensitivity of Fonsecaea pedrosoi to ketoconazole, itra-conazole and saperconazole. Mem& Inst Oswaldo Cruz 1996; 91(6): 779–784.
   PubMed Web of Science ®Google Scholar
• Bedout C, Gómez BL, Restrepo A. In vitro susceptibility testing of Fonsecaea pedrosoi to antifungals. Rev Inst Med Trop S Paulo 1997; 39 (3): 145–148.
   PubMedGoogle Scholar
• National Committee for Clinical and Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Proposed Standard, 1992. Document M-27-P. Villanova, PA: National Committee for Clinical and Labora-tory Standards.
   Google Scholar
• Espinel-Ingroff A, Kerkering TM. Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi. J Clin Microbiol 1991; 29: 393–394.
   Google Scholar
• Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995; 39: 314–319.
   PubMed Web of Science ®Google Scholar
• Gomes MHR, Resende MA. Fonsecaea pedrosoi: lipid composi-tion and determination of susceptibility to amphotericin B. Can J Microbiol 1992; 38 (3): 209–214.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Standardization of antifungal susceptibility testing: review update. Rev Iberolatinoamer Micol 1996; 13: S64–S68.
   Google Scholar
• Van Cutsem J. An investigation of the in vitro activity and antifungal spectrum of itraconazole and terbinafine in relation with in vivo efficacy in dermatophytosis and other mycoses. J Mycol Med 1994; 4: 137–144.
   Google Scholar
• Vanden Bossche H, Warnock WD, Dupont B, et al. Mecha-nisms and clinical impact of drug resistance. J Med Vet Mycol 1994; 32 (Supp. 1): 189–202.
   Google Scholar
• Scholer HJ, Polak A. Resistance to systemic antifungal agents. In: Bryan LE, ed. Antimicrobial Drug Resistance. Orlando: Academic Press, 1984; 393–460.
   Google Scholar
• Fung-Tomc JC, Huczko E, Minassian B, Bonner DP. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). An-timicrob Agents Chemother 1998; 42 (2): 313–318.
   Google Scholar
• Oliveira LG, Resende MA, Cisalpino EO, Figueiredo YP, Lopes CF. In vitro sensivity to 5-fluorocytosine of strains isolated from patients under treatment for chromomycosis. Intern J Dermatol 1975; 14 (2): 141–143.
   Google Scholar
• Pujol I, Guarro J, Llop C, et al. Comparison study of broth susceptibility tests for the filamentous fungi. Antimicrob Agents Chemother 1996; 40: 2106–2110.
   PubMed Web of Science ®Google Scholar
• McGinnis MR, Pasarell L. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. Med Mycol 1998; 36: 243–246.
   PubMed Web of Science ®Google Scholar
• McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CR, Rinaldi MG. In vitro activity of voriconazole against selected fungi. Med Mycol 1998; 36: 239–242.
   PubMed Web of Science ®Google Scholar
• Lopes CF. Recent developments in the therapy of chromoblas-tomycosis. Bull Pan Am Health Organ 1981; 15: 58–64.
   PubMedGoogle Scholar
• Tuffanelli L, Milburn PB. Treatment of chromoblastomycosis. J Am Acad Dermatol 1990; 23: 728–732.
   PubMed Web of Science ®Google Scholar
• Queiroz-Telles F, Purim KS, Boguszewski CL, Afonso FCS, Graf H. Adrenal response to corticotrophin and testosterone during long-term therapy with itraconazole in patients with chromoblastomycosis. J Antimicrob Chemother 1997; 40: 899–902.
   Google Scholar
• Kullavanijaya P, Rojanavanich V. Successful treatment of chro-moblastomycosis due to Fonsecaea pedrosoi by the combination of itraconazole and cryotherapy. Int J Dermatol 1995; 34: 804–807.
   PubMed Web of Science ®Google Scholar
• Whittle DI, Kominos S. Use of itraconazole for treating subcu-taneous phaeohyphomycosis caused by Exophiala jeanselmei. Clin Infect Dis 1995; 19: 339–341.
   Google Scholar
• Yu RY, Gao L. Chromoblastomycosis successfully treated with fluconazole. Int J Dermatol 1994; 33: 716–719.
   PubMed Web of Science ®Google Scholar
• Yang SP, Liu CY, Cheng NC, Lee WS, Liu CE, Kuo BI. Successful treatment of subcutaneous mycoses with fluconazole: a report of two cases. Ghung Hua I Hsueh Tsa Chih 1995; 56 (6): 432–435.
   Google Scholar
• Guerriero C, Simone C, Tulli A. A case of chromoblastomyco-sis due to Phialophora verrucosa responding to treatment with fluconazole. Eur J Dermatol 1998; 8 (3): 67–168.
   Google Scholar